Resultados de procura - Shuyang Zhu

Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutati... por Yuankai Shi, Gongyan Chen, Xiang Wang, Yunpeng Liu, Lin Wu, Yanrong Hao, Chunling Liu, Shuyang Zhu, Xiaodong Zhang, Yuping Li, Jiwei Liu, Lejie Cao, Ying Cheng, Hui Zhao, Shucai Zhang, Aimin Zang, Jiuwei Cui, Jian Feng, Nong Yang, Jie Hu, Fei Liu, Yong Jiang, Nan Ge

Connect to this object online.